Janssen Search
Search results
Investigational Ebola Vaccine in Sierra Leone
Maximizing the Impact of our Awareness and Development Efforts for an Investigational Ebola Vaccine in Sierra Leone The road to the EBOVAC-Salone clinic in Kambia, Sierra Leone The clinic, in Kambia, Sierra Leone, where the EBOVAC-Salone trial took place. ...
Pascale Marty-Ethgen, Pharm.D., Ph.D.
PASCALE MARTY-ETHGEN, PHARM.D., PH.D. VICE PRESIDENT PORTFOLIO MANAGEMENT AND EXTERNAL INNOVATION Pascale Marty-Ethgen, Pharm.D., Ph.D. is Vice President, Immunology Therapeutic Area Portfolio Management and External Innovation Leader for Janssen Research ...
TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study
Jan 22, 2024 United States Data illustrates rapid and significant clearance in moderate to severe scalp psoriasis and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory ...
Bacterial Infections
Bacterial Infections We refuse to stand still while bacterial infections continue to evade our control. Structure of E. coli We are working urgently to help protect society from the consequences of Extraintestinal Pathogenic E. coli (ExPEC) and ...
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant P
Mar 01, 2023 United States Niraparib and Abiraterone Acetate Plus Prednisone Has Potential to Address Unmet Need for Patients with BRCA-Positive mCRPC RARITAN, N.J., February 28, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
Commitment to Gastroenterology
Welcome to the Johnson & Johnson Gastroenterology Newsroom! Below, please find the latest on our Gastroenterology news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines ...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Jul 02, 2024 CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J., (July 2, 2024) /PRNewswire/ – ...
Tamas Oravecz, Ph.D.
TAMAS ORAVECZ, Ph.D. SENIOR DIRECTOR HEAD OF EXPLORATORY BIOLOGY Tamas Oravecz, Ph.D., is Senior Director and Head of Exploratory Biology within Janssen BioTherapeutics (JBIO), Janssen Research & Development. He is based at Spring House, PA. His team ...
Michael Plotnick, M.D.
MICHAEL PLOTNICK, M.D. VICE PRESIDENT GLOBAL MEDICAL AFFAIRS IMMUNOLOGY Michael Plotnick, M.D. is Vice President, Global Medical Affairs for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, he leads a team ...
Our Fight Against Alzheimer’s
Our Fight Against Alzheimer’s September is World Alzheimer’s Month, a tradition that began in 2012 to draw attention to this devastating brain disease. It is easy to get discouraged about Alzheimer’s. Worldwide, nearly 44 million people have Alzheimer’s ...